Aktienanalyse zu Vistagen Therapeutics Inc (VTGN)VTGNVistagen Therapeutics Inc

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Vistagen Therapeutics is currently not a strong buy. The stock is trading at $0.2529, and while it has shown a 3.65% increase over the past five days, it has a staggering year-to-date decline of 62.75%. The RSI is at 48.935, indicating a neutral position, and the forward P/E ratio is 0, reflecting uncertainty in future earnings. The main risk is the recent trial failure which caused a significant drop in stock price, highlighting potential volatility ahead.

1 analysts cover VTGN: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 0.97.